

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 November 2021 (25.11.2021)



(10) International Publication Number
WO 2021/234366 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 38/095 (2019.01)
A61K 9/16 (2006.01) A61P 13/00 (2006.01)
A61K 31/00 (2006.01) A61K 38/00 (2006.01)

(21) International Application Number:

PCT/GB2021/051191

(22) International Filing Date:

18 May 2021 (18.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2007306.0	18 May 2020 (18.05.2020)	GB
2009905.7	29 June 2020 (29.06.2020)	GB
2018901.5	01 December 2020 (01.12.2020)	GB

(71) Applicant: **OREXO AB** [SE/SE]; PO Box 303, SE-751 05 Uppsala (SE).

(72) Inventors: **SÄVMARKER, Jonas**; PO Box 303, SE-751 05 Uppsala (SE). **RÖNN, Robert**; PO Box 303, SE-751 05 Uppsala (SE). **FISCHER, Andreas**; PO Box 303, SE-751 05 Uppsala (SE).

(74) Agent: **MCNEENEY, Stephen Phillip**; Potter Clarkson, The Belgrave Centre, Talbot Street, Nottingham Nottinghamshire NG1 5GG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

(54) Title: NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY




Figure 10

(57) Abstract: According to the invention, there is provided a pharmaceutically-acceptable composition which is preferably in the form of a spray-dried powder comprising a mixture of: (a) a pharmaceutically-effective dosage amount of at least one pharmaceutically-active compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Compositions are suitable for, for example, transmucosal drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrans (e.g. cyclodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.

[Continued on next page]



WO 2021/234366 A1

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))